Tag Archive for: Alchemab Therapeutics

Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension

/in

Follows successful completion of pre-clinical activities by Alchemab as part of earlier licensing deal with Eli Lilly and Company for ATLX-1282 Financing included participation from Eli Lilly and Company and Ono Venture Investment alongside significant support from world-class existing investors  Cambridge, UK, 9 September 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company which identifies and develops […]

Read more

Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company

/in

– New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism – Deal worth up to $415m including upfront and downstream, plus royalties on top – ATLX-1282 is the first programme out of Alchemab’s entirely novel platform which generates and analyses millions of antibody sequences […]

Read more

Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS

/in

Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab’s antibody discovery platform. Cambridge, UK, 9 January 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces it has entered a collaboration with Lilly to discover novel […]

Read more

Optimum’s hot topic: Can we ‘bottle’ the remarkable biology of people who, against all odds, beat killer diseases?

/in

By Stephen Adams, Optimum Strategic Communications   Nature has been an inspiration behind the development of many drugs, starting with the humble aspirin, which was originally derived from willow bark.  But what if we could learn the secrets of what gives some people the incredible ability to overcome the most serious diseases?  What if we could […]

Read more

Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer

/in

Cambridge, UK, 12 September 2024 – Alchemab Therapeutics (Alchemab), a pharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that Jane Osbourn, OBE, FMEDSCI, PhD, Alchemab’s Chief Scientific Officer (CSO), has succeeded Young Kwon, PhD as Chief Executive Officer (CEO) and member of the Board. Read more…

Read more